Cancer Immunotherapy Market Size Worth USD 673.08 Billion by 2034 | CAGR: 11.90%
The global cancer immunotherapy market size is expected to reach USD 673.08 Billion by 2034, according to a new study by Polaris Market Research. The report “Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report, By Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators); By Application; By End-User; By Region; Segment Forecast, 2025 - 2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The cancer immunotherapy market is growing due to the increasing incidence of cancer, the expanding effectiveness and accuracy of newer therapies, the rising adoption of target therapy, and increasing R&D activities for new drug development. Over 1,000 clinical trials for treating cancer with immune-based therapies are currently underway worldwide in various phases of development, as per the NCT Registry as of September 8, 2020. With the ongoing development of these therapies, players can expect the emergence of new and effective immunotherapies for cancer, provided trials continue to yield positive results.
The research and development of cancer immunotherapy is faced with a significant challenge in developing countries due to its high cost, making it difficult for treatment to receive adequate funding. Substantial investment is required for implementing innovative research, which is also a major concern. Due to the high cost of cancer immunotherapy, major companies are hesitant to enter this market, and their profitability prospects remain uncertain. These factors collectively hinder the growth of the cancer immunotherapy market.
Advances in immunology have played a pivotal role in driving the growth and expansion of the cancer Immunotherapy market. Immunology, the study of the immune system and its response to various diseases, has witnessed significant breakthroughs in recent years. These advancements have led to a deeper understanding of the complex interactions between cancer cells and the immune system, paving the way for the development of innovative immunotherapies that are revolutionizing cancer treatment. The growing understanding of immunology has also fostered collaboration between academia, pharmaceutical companies, and research institutions. These collaborations have accelerated the pace of drug development and clinical trials in the field of cancer Immunotherapy. The collective efforts of scientists, clinicians, and industry leaders have resulted in a robust pipeline of novel immunotherapies, offering hope to patients with various cancer types.
Cancer Immunotherapy Market Report Highlights
- In 2023, monoclonal antibodies gained a significant share in the global market due to their specialized ability to target specific molecules on either cancer cells or immune cells. This targeted approach facilitated the immune system's recognition and combat of cancer more effectively, making monoclonal antibodies the dominant segment in the global market.
- The hospital segment is anticipated to grow with a significant CAGR in the forecasted years owing to increased healthcare expenditures, which have led to a rise in the use of Immunotherapy drugs in hospitals and clinics worldwide.
- In the global market, North America dominated the market due to the increased accessibility of advanced cancer immunotherapies for patients in the region, the presence of notable market players, and the substantial investments made by both governmental and non-governmental organizations in cancer immunotherapy research and development.
- The global key market players include Amgen Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, OSE Immunotherapeutics, etc.
Request a free sample copy or read the full market insights: Cancer Immunotherapy Market
Polaris Market Research has segmented the cancer immunotherapy market report based on type, application, end-user, and region:
Cancer Immunotherapy, Type Outlook (Revenue - USD Billion, 2020 - 2034)
- Monoclonal Antibodies
- Cancer Vaccines
- Check Point Inhibitors & Immunomodulators
Cancer Immunotherapy, Application Outlook (Revenue - USD Billion, 2020 - 2034)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head & Neck Cancer
- Others
Cancer Immunotherapy, End-User Outlook (Revenue - USD Billion, 2020 - 2034)
- Hospitals
- Clinics
- Cancer Research Centers
Cancer Immunotherapy, Regional Outlook (Revenue - USD Billion, 2020 - 2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Austria
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of APAC
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of MEA
Cancer Immunotherapy Market Report Scope
| Report Attributes | Details |
| Market size value in 2025 | USD 251.56 billion |
| Revenue forecast in 2034 | USD 673.08 billion |
| CAGR | 11.90% from 2025 – 2034 |
| Base year | 2024 |
| Historical data | 2020 – 2023 |
| Forecast period | 2025 – 2034 |
| Quantitative units | Revenue in USD billion and CAGR from 2025 to 2034 |
| Segments covered | By Type, By Application, By End-User, By Region |
| Regional scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Customization | Report customization as per your requirements with respect to countries, region, and segmentation. |
| For Specific Research Requirements |
